BioSpace News Archive

Expanded Patent Portfolio Now Includes U.S., Europe and Japan

Viome will combine its personalized food recommendations based on insights from the microbiome with Habit’s unique nutrition plans and engagement tools to offer the first “whole-body” approach to human health.

- Series A Round led by strategic investor Pharmagest - Welcomes Techstars as an investor and selected into elite Techstars Alchemist Blockchain Accelerator in New York

Seattle Genetics, Inc. announced that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time.

Toothpaste is just one of many tooth-damaging fluoride sources children are exposed to, reports the New York State Coalition Opposed to Fluoridation, Inc.

Interested parties are invited to go to https://backend.otcmarkets.com/otcapi/company/dns/news/document/34780/content for the full letter.

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding the Company’s submission of a proposed trial design for the treatment of KL4 Osteoarthritis patients with Ampion

The BIO CEO & Investor Conference is taking place February 11-12, 2019 in New York City.

Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that Chris Xu, PhD, chief executive officer, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019 at 10:30 am ET.

Culturelle®, the leading probiotic brand, and Persona™ Nutrition, the top personalized vitamin program, today announced a partnership to deliver Culturelle probiotic through Persona’s personalized nutrition program. Culturelle will be paired with Persona’s Foundational™ Multi to optimize overall health.